In WT KRAS mCRC , PFS was improved , objective response was higher , and there was a trend toward improved OS with panitumumab-FOLFOX@ , with significant improvement in OS observed in an updated analysis of survival in patients with WT KRAS mCRC treated with panitumumab + FOLFOX@ versus FOLFOX@ alone ( P = @ ) .